Impact of diverse aortic pathologies on outcomes after transapical transcatheter aortic valve replacement. Issue 7 (30th March 2021)

• Record Type: Journal Article
• Authors: Useini, Dritan; Beluli, Blerta; Christ, Hildegard; Strauch, Justus
• Is Part Of: Journal of cardiac surgery. Volume 36:Issue 7(2021)
• Page Start: 2240
• Page End: 2246
• Publication Date: 2021-03-30
• Subjects: aorta no‐touch -- diverse aortic pathologies -- TAVR; Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.15516
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: Objectives: Some patients who undergo transcatheter aortic valve replacement (TAVR) have a concomitant diverse aortic pathologies (AP). They are usually considered high‐risk candidates for the procedure and require further assessment to determine the best vascular approach. The impact of these AP on TAVR is not well known as the information is scarce. We aimed to evaluate midterm clinical impact of different AP after transapical (TA)‐TAVR. Methods: Twenty patients with atherosclerotic/occluding aortic diseases (A/OAD) (porcelain aorta, Leriche Syndrome, penetrating aortic ulcer, and aortic thrombus), 24 patients with aortic morphologic diseases (AMD) (thoracic/abdominal aortic aneurysms, aortic kinking, aortic type B dissection, aortic elongation/tortuosity, and previous aortic intervention), and 11 patients with combined aortic diseases (CAD) underwent TA‐TAVR treatment between January 2011 and November 2019 at our center. We conducted up to 5‐years clinical follow‐up. Results: All patients were classified in the heart team as a high interventional risk. The 30‐day mortality and stroke were 5% and 10% in the A/OAD, 8.3% and 0% in the AMD, and 0% and 0% in the CAD, respectively. The median time of freedom from a composite of death and cardio‐cerebral adverse events was 22.1 months [95% confidence interval [CI]: 9.9–34.3] in A/OAD versus 34.3 months [95% CI: 15.6–53] in AMD versus 17 months [95% CI: 0–39.4] in CAD; p = .525. We registered neither procedural aortic injury nor aortic syndrome at follow‐up. The moderate/severe paravalvular leakage rates were 5%, 0% and 0% in the A/OAD, AMD and CAD, respectively. Conclusion: Independent of underlying AP, the TA‐TAVR is a safe method and shows very promising early and midterm outcomes in patients with various AP.